Abstract
Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Drug Resistance, Neoplasm
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / genetics
-
ErbB Receptors / immunology
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Mutation
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
Substances
-
Antibodies, Monoclonal
-
Protein Kinase Inhibitors
-
EGFR protein, human
-
ErbB Receptors